Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$2.74 USD
+0.03 (1.11%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.74 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TSHA 2.74 +0.03(1.11%)
Will TSHA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TSHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSHA
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade
TSHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Other News for TSHA
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | TSHA ...
Taysha Gene Therapies (TSHA) Receives 'Buy' Rating from B of A Securities | TSHA Stock News
BofA Assigns Buy Rating to Taysha Gene Therapies (TSHA) with $8 Target | TSHA Stock News
Taysha Gene Therapies initiated with bullish view at BofA, here's why
Taysha Gene Therapies initiated with bullish view at BofA